Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTOR | P42345 | 5/20 | 0.37 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.34 |
| ▸ | PRKDC | P78527 | 4/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.32 |
| ▸ | ATR | Q13535 | 6/20 | 0.32 |
| ▸ | ABL1 | P00519 | 1/20 | 0.32 |
| ▸ | BCR | P11274 | 1/20 | 0.32 |
| ▸ | BRD4 | O60885 | 2/20 | 0.31 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.31 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.31 |
| ▸ | ATRIP | Q8WXE1 | 1/20 | 0.31 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.31 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.31 |
| ▸ | RICTOR | Q6R327 | 1/20 | 0.31 |
| ▸ | RPTOR | Q8N122 | 1/20 | 0.31 |
| ▸ | MAPKAP1 | Q9BPZ7 | 1/20 | 0.31 |
| ▸ | MLST8 | Q9BVC4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2689464 | 0.82 | PDE2A (0.37) | PIK3CAPRKDCSMN1; SMN2PIK3CDABL1 | |
| SCHEMBL2689918 | 0.81 | PDE2A (0.38) | PIK3CASMN1; SMN2ABL1BCRBRD4 | |
| SCHEMBL2689540 | 0.81 | PDE2A (0.37) | SMN1; SMN2ABL1BCRBRD4 | |
| SCHEMBL1288265 | 0.78 | MTOR (0.33) | MTORPIK3CAPRKDCSMN1; SMN2PIK3CD | |
| SCHEMBL5943284 | 0.76 | BRD4 (0.32) | PRKDCBRD4 | |
| SCHEMBL2337312 | 0.75 | PIK3CA (0.41) | MTORPIK3CASMN1; SMN2PIK3CDABL1 | |
| SCHEMBL10286392 | 0.73 | PLK1 (0.49) | MTORPIK3CAATRATRIP | |
| SCHEMBL2071278 | 0.73 | MTOR (0.40) | MTORPIK3CAPRKDCPIK3CDPIK3R1 | |
| SCHEMBL2688793 | 0.72 | PLK1 (0.42) | PRKDCBRD4 | |
| SCHEMBL5928761 | 0.72 | PLK1 (0.42) | PRKDCBRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120115848-A1 | Inhibitors of Polo-Like Kinase | ELAN PHARMACEUTICALS, INC. (US) | 2012-05-10 | — | — | US | disclosed |
| US-20120115848-A1 | Inhibitors of Polo-Like Kinase | ELAN PHARMACEUTICALS, INC. (US) | 2012-05-10 | — | — | US | disclosed |
| US-20120115848-A1 | Inhibitors of Polo-Like Kinase | ELAN PHARMACEUTICALS, INC. (US) | 2012-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115848-A1 | Inhibitors of Polo-Like Kinase | PLK1, POLR2E, POLR2H | MTOR 594/4885PIK3CA 184/4885PRKDC 71/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.